Cargando…
Current Status of New Anticoagulants in the Management of Venous Thromboembolism
Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and proph...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310205/ https://www.ncbi.nlm.nih.gov/pubmed/22496694 http://dx.doi.org/10.1155/2012/856341 |
_version_ | 1782227628231491584 |
---|---|
author | Montoya, Roberto C. Gajra, Ajeet |
author_facet | Montoya, Roberto C. Gajra, Ajeet |
author_sort | Montoya, Roberto C. |
collection | PubMed |
description | Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and prophylaxis, and have demonstrated their efficacy in a vast number of previous studies. Despite their broad use, these agents have important limitations that have led to the development of new drugs in a bid to overcome the disadvantages of the old ones without decreasing their therapeutic effect. These novel medications, some approved and others in different stages of development, include direct thrombin inhibitors like dabigatran etexilate, and direct activated factor X inhibitors like rivaroxaban. The current paper will review the characteristics, clinical trial results, and current and potential therapeutic uses of these new agents with a focus on the categories of direct thrombin inhibitors and activated factor X inhibitors. |
format | Online Article Text |
id | pubmed-3310205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33102052012-04-11 Current Status of New Anticoagulants in the Management of Venous Thromboembolism Montoya, Roberto C. Gajra, Ajeet Adv Hematol Review Article Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and prophylaxis, and have demonstrated their efficacy in a vast number of previous studies. Despite their broad use, these agents have important limitations that have led to the development of new drugs in a bid to overcome the disadvantages of the old ones without decreasing their therapeutic effect. These novel medications, some approved and others in different stages of development, include direct thrombin inhibitors like dabigatran etexilate, and direct activated factor X inhibitors like rivaroxaban. The current paper will review the characteristics, clinical trial results, and current and potential therapeutic uses of these new agents with a focus on the categories of direct thrombin inhibitors and activated factor X inhibitors. Hindawi Publishing Corporation 2012 2012-03-08 /pmc/articles/PMC3310205/ /pubmed/22496694 http://dx.doi.org/10.1155/2012/856341 Text en Copyright © 2012 R. C. Montoya and A. Gajra. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Montoya, Roberto C. Gajra, Ajeet Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
title | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
title_full | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
title_fullStr | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
title_full_unstemmed | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
title_short | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
title_sort | current status of new anticoagulants in the management of venous thromboembolism |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310205/ https://www.ncbi.nlm.nih.gov/pubmed/22496694 http://dx.doi.org/10.1155/2012/856341 |
work_keys_str_mv | AT montoyarobertoc currentstatusofnewanticoagulantsinthemanagementofvenousthromboembolism AT gajraajeet currentstatusofnewanticoagulantsinthemanagementofvenousthromboembolism |